Crinetics Pharmaceuticals (CRNX) Misses Q4 EPS by 4c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q4 EPS of ($0.90), $0.04 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $0 versus the consensus estimate of $197.1 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Wolfe upgrades AT&T to Outperform as improving fundamentals outweigh Starlink risk
• Towne Bank (TOWN) Misses Q2 EPS by 1c
• Esquire Financial Holdings, Inc. (ESQ) Tops Q2 EPS by 5c